Skip to main content
OpenTrials

Clinical trial condition

Urologic Diseases

Explore clinical trials studying Urologic Diseases. Study availability and eligibility vary by location and protocol.

13,717 public trials 2,164 recruiting studies
Refine in advanced search Browse all conditions

Urologic Diseases trial results

Active, not recruiting

Pivotal Study of Voro Urologic Scaffold

NCT06873581

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, +11 more
Locations
  • Mayo Clinic Phoenix, Arizona, United States
  • Academic Urology Sun City, Arizona, United States
  • University of California Los Angeles Los Angeles, California, United States
  • University of California San Diego San Diego, California, United States
View all 19 locations
View Trial Details
Active, not recruiting

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

NCT03237780

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Locally Advanced Bladder Urothelial Carcinoma, +36 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Keck Medicine of USC Buena Park Buena Park, California, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • City of Hope at Irvine Lennar Irvine, California, United States
View all 21 locations
View Trial Details
Active, not recruiting

Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

NCT03284385

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +24 more
Locations
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • UCSF Medical Center-Mount Zion San Francisco, California, United States
  • UCSF Medical Center-Mission Bay San Francisco, California, United States
View all 29 locations
View Trial Details
Active, not recruiting

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

NCT04640623

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, +8 more
Locations
  • Del Sol Research Management, LLC Tucson, Arizona, United States
  • University of Southern California Los Angeles, California, United States
  • Genesis Healthcare Partners - Genesis Research Greater Los Angeles Sherman Oaks, California, United States
  • The Urology Center of Colorado Denver, Colorado, United States
View all 144 locations
View Trial Details
Active, not recruiting

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

NCT05138133

Conditions
Autoimmune Diseases, Connective Tissue Diseases, Female Urogenital Diseases, +11 more
Locations
  • Research Site Glendale, Arizona, United States
  • Research Site La Palma, California, United States
  • Research Site Los Angeles, California, United States
  • Research Site Upland, California, United States
View all 164 locations
View Trial Details
Active, not recruiting

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

NCT05316155

Conditions
Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +12 more
Locations
  • University of Alabama at Birmingham - The Kirklin Clinic Birmingham, Alabama, United States
  • University of Southern California Los Angeles, California, United States
  • Urology Associates of Denver Lone Tree, Colorado, United States
  • Urological Research Network Hialeah, Florida, United States
View all 59 locations
View Trial Details
Active, not recruiting

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

NCT04557462

Conditions
Autoimmune Diseases, Chronic Disease, Disease Attributes, +15 more
Locations
  • AZ Kidney Dise and Hypertension Ctr Glendale, Arizona, United States
  • Kaiser Permanente San Diego, California, United States
  • North America Research Institute San Dimas, California, United States
  • University of Colorado Anschutz Aurora, Colorado, United States
View all 155 locations
View Trial Details
Active, not recruiting

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

NCT06734234

Conditions
Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, +12 more
Locations
  • GSK Investigational Site Rochester, Minnesota, United States
  • GSK Investigational Site Brussels, Belgium
  • GSK Investigational Site Ghent, Belgium
  • GSK Investigational Site Leuven, Belgium
View all 23 locations
View Trial Details
Active, not recruiting

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

NCT04626518

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • University of California at San Francisco ( Site 3008) San Francisco, California, United States
  • Yale-New Haven Hospital-Yale Cancer Center ( Site 3011) New Haven, Connecticut, United States
  • University of Chicago ( Site 3013) Chicago, Illinois, United States
  • University of Iowa ( Site 3012) Iowa City, Iowa, United States
View all 51 locations
View Trial Details

Related conditions